Abstract
Genetic variants of SARS-CoV-2 have repeatedly altered the course of the COVID-19 pandemic. Delta variants of concern are now the focus of intense international attention because they are causing widespread COVID-19 disease globally and are associated with vaccine breakthrough cases. We sequenced the genomes of 12,221 SARS-CoV-2 from samples acquired March 15, 2021 through August 26, 2021 in the Houston Methodist hospital system. This sample represents 88% of all Methodist system COVID-19 patients during the study period. Delta variants increased rapidly from late April onward to cause 99.7% of all COVID-19 cases and spread throughout the Houston metroplex. Compared to other variants, Delta caused a significantly higher rate of vaccine breakthrough cases (23.4% compared to 6.2% for all other variants combined). Importantly, significantly fewer fully vaccinated individuals required hospitalization. Individuals with vaccine breakthrough cases caused by Delta had a low median PCR cycle threshold (Ct) value (a proxy for high virus load). This value was closely similar to the median Ct value for unvaccinated patients with COVID-19 caused by Delta variants, suggesting that fully vaccinated individuals can transmit SARS-CoV-2 to others. Patients infected with Alpha and Delta variants had several significant differences. Our integrated analysis emphasizes that vaccines used in the United States are highly effective in decreasing severe COVID-19 disease, hospitalizations, and deaths.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research was supported by the Houston Methodist Academic Institute Infectious Diseases Fund and many generous Houston philanthropists. James Davis was funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93019C00076.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was approved by the Houston Methodist Research institutional review board (IRB1010-0199).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosures: None.
Funding: This project was supported by the Houston Methodist Academic Institute Infectious Diseases Fund; and supported in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93019C00076 (J.J.D. and R.O.).
Revision includes updated SARS-CoV-2 genome sequence data for Houston Methodist cases occurring through August 26, 2021.
Data Availability
Genome data used in this study have been deposited to GISAID.
